Business
INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference
SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted Fireside Chat discussing the business and conducting 1x1 virtual investor meetings.\n\n \n \n \n \n \n \n\n \nThe webcasted Fireside Chat will be available for viewing at 11:00am ET on Monday, December 13, 2021 at https://wsw.com/webcast/lytham3/invo/2053560. The webcast will also be available for replay following the event.\nTo arrange a 1x1 meeting with management, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/winter2021invreg.\nAbout INVO Bioscience\nWe are a medical device company focused on creating simplified, affordable treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit https://www.invobioscience.com/ \nSafe Harbor Statement\nThis release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunit...